Cost-effectiveness of warfarin: Trial versus “real-world” stroke prevention in atrial fibrillation
- 30 June 2009
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 157 (6) , 1064-1073
- https://doi.org/10.1016/j.ahj.2009.03.022
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 44 references indexed in Scilit:
- Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studiesBMJ, 2008
- Death and Disability from Warfarin-Associated Intracranial and Extracranial HemorrhagesThe American Journal of Medicine, 2007
- Preference-Based EQ-5D Index Scores for Chronic Conditions in the United StatesMedical Decision Making, 2006
- Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation StudyJournal of the American Geriatrics Society, 2006
- The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the USPharmacoEconomics, 2006
- Atrial Fibrillation Is Associated with Severe Acute Ischemic StrokeNeuroepidemiology, 2003
- The Utility of Health States After StrokeStroke, 2001
- Stroke Severity in Atrial FibrillationStroke, 1996
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Probability of stroke: a risk profile from the Framingham Study.Stroke, 1991